Needham & Company
-
Needham: 'we believe that IMDX is making good progress towards its GraftAssureDx submissions'
-
Insight Molecular Diagnostics Inc. (IMDX) PT Raised to $9 at Needham
-
Needham Reiterates Buy Rating on Insight Molecular Diagnostics Inc. (IMDX)
-
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

